Loading
How much of the FLT3 gene in the leukaemia carries the internal duplication, measured as the ratio of mutant to normal copies. The 2017 European LeukemiaNet guidelines used it to grade risk; the 2022 update dropped it because midostaurin and quizartinib help regardless of the ratio.
Ratio of mutant to wild-type FLT3-ITD alleles by fragment analysis; ≥0.5 was 'high'. ELN 2017 used it for risk; ELN 2022 removed it, treating all FLT3-ITD as intermediate risk given midostaurin and quizartinib benefit across ratios. Still reported by many labs and relevant to interpreting older trials.
In plain words · FLT3 is a kinase mutated in about a third of acute myeloid leukaemias, where adding an inhibitor to chemotherapy improves survival.
Showing the target this term concerns: FLT3.
The glossary entry explains the word; the readout page carries the scoring rule, the thresholds approvals use, the companion diagnostics and the tests.
Shares FLT3-ITD (internal tandem duplication), FLT3, FLT3-mutated acute myeloid leukaemia, Acute myeloid leukaemia.
Shares RATIFY (CALGB 10603), FLT3, FLT3-mutated acute myeloid leukaemia, Acute myeloid leukaemia.
Shares RATIFY (CALGB 10603), FLT3-mutated acute myeloid leukaemia.
Shares RATIFY (CALGB 10603), FLT3, Acute myeloid leukaemia.
Shares FLT3, FLT3-mutated acute myeloid leukaemia, Acute myeloid leukaemia.
Shares FLT3, Acute myeloid leukaemia.
Shares FLT3-ITD (internal tandem duplication), RATIFY (CALGB 10603), FLT3, FLT3-mutated acute myeloid leukaemia.
Shares FLT3-ITD (internal tandem duplication), FLT3, FLT3-mutated acute myeloid leukaemia, Acute myeloid leukaemia.